Author/Creator: Teng, L. - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator Teng, L.

1. FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1). (15th July 2016)

Authors:: Kavanaugh, A.; Gladman, D.D.; Gomez-Reino, J.J.; Hall, S.; Lespessailles, E.; Mease, P.J.; Schett, G.; McIlraith, M.; Shah, K.; Teng, L.; Wollenhaupt, J.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 75(2016)Supplement 2
Page Start:: 597
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. THU0432 Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase III, Randomized, Controlled Trials. (15th July 2016)

Authors:: Kavanaugh, A.; Gladman, D.D.; Edwards, C.J.; Poder, A.; Lioté, F.; Bird, P.; Schett, G.; Nguyen, D.; Teng, L.; Mease, P.J.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 75(2016)Supplement 2
Page Start:: 346
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. THU0435 DAS-28 Remission and Improvements in Skin Disease over 3 Years of Treatment with Apremilast: Results from The Palace 3 Study in Dmard/biologic-Experienced Active PsA Patients. (15th July 2016)

Authors:: Edwards, C.J.; Blanco, F.J.; Crowley, J.; McIlraith, M.; Shah, K.; Teng, L.; Birbara, C.A.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 75(2016)Supplement 2
Page Start:: 347
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. FRI0352 PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION WITH APREMILAST TREATMENT AMONG DMARD-NAIVE SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS. (2nd June 2020)

Authors:: Mease, P. J.; Kavanaugh, A.; Ogdie, A.; Wells, A. F.; Bergman, M.; Gladman, D. D.; Behrens, F.; Richter, S.; Brunori, M.; Teng, L.; Guerette, B.; Smolen, J. S.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 79(2020)Supplement 1
Page Start:: 771
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. AB0927 Probability and impact of achieving low disease activity or remission in patients with psoriatic arthritis treated with apremilast: pooled analysis of the palace 1–3 phase 3 trials. (12th June 2018)

Authors:: McInnes, I.; Mease, P.J.; Behrens, F.; Orbai, A.-M.; Brunori, M.; Teng, L.; Guerette, B.; Smolen, J.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 1588
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial. (12th June 2018)

Authors:: Nash, P.; Ohson, K.; Walsh, J.; Delev, N.; Nguyen, D.; Teng, L.; Paris, M.; Gomez-Reino, J.J.; Aelion, J.A.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 1596
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. OP0309 Characterisation of clinical benefits in subjects classified as acr20 non-responders at week 104 of apremilast treatment: subanalysis of 3 long-term, phase iii trials. (12th June 2018)

Authors:: Mease, P.; Gladman, D.; Kavanaugh, A.; Nakasato, P.; Guerette, B.; Teng, L.; Nash, P.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 201
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. AB0946 Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÏve subjects with active psoriatic arthritis. (12th June 2018)

Authors:: Mease, P.J.; Gladman, D.D.; Davenport, E.K.; Zhou, X.; Guerette, B.; Teng, L.; Kaura, S.; Nash, P.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 1598
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

9. SAT0347 Baseline characteristics of patients with psoriatic arthritis initiated on apremilast in the corrona psoriatic arthritis/spondyloarthritis (PSA/SPA) registry. (12th June 2018)

Authors:: Mease, P.J.; Rosenstein, E.; Feng, H.; Liu, M.; Guerette, B.; Teng, L.; Rebello, S.; Ogdie-Beatty, A.R.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 1039
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

10. AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis. (12th June 2018)

Authors:: Wells, A.F.; Edwards, C.J.; Kivitz, A.J.; Bird, P.; Guerette, B.; Delev, N.; Paris, M.; Teng, L.; Aelion, J.A.
Journal:: Annals of the rheumatic diseases
Issue:: Volume 77(2018)Supplement 2
Page Start:: 1576
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗